Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
Healthcare
$2.98 -3.18%
-$0.16 today
- Market cap
- $69.90M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
52W Low $3.71High $7.75
Volume 0.07M
Average 0.16M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$10.74M
FY 2025 · Annual
Investing Cash Flow
-$1.16M
FY 2025 · Annual
Financing Cash Flow
$20.39M
FY 2025 · Annual
+27.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$21.2M
+ D&A$27.4K
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
+ Working Capital$3.9M
+ Other Non-Cash$2.3M
= Operating Cash Flow-$10.7M
- Capex$0
= Free Cash Flow-$10.7M
Analysis
FY2025 free cash flow is -$10.7M. FCF conversion is 50.6% of net income. Operating cash flow was -$10.7M, with capex of $0. The largest bridge item is Stock-Based Comp at $4.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 8-K | Current report | Oct 5, 2026 | |
| 8-K | Current report | Sep 15, 2026 |
Does COYA generate free cash flow?
Coya Therapeutics, Inc. (COYA) generated -$10.74M of free cash flow in fiscal 2025.
How much operating cash flow does COYA produce?
Operating cash flow was -$10.74M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.